Source:http://linkedlifedata.com/resource/pubmed/id/15467302
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2005-1-3
|
| pubmed:abstractText |
Aldosterone blockade reduces morbidity and mortality in patients with heart failure. We studied the effects of eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy after autoimmune myocarditis. Twenty-eight days after immunization, the surviving Lewis rats were randomized to 1 month's oral treatment with low-dose eplerenone (group L), high-dose eplerenone (group H) or vehicle (group V). Five of 15 (33%) rats in group V and 3 of 15 (20%) rats in group L died during the course of treatment. High-dose eplerenone significantly reduced cardiomyocyte hypertrophy, heart weight and heart weight to body weight ratio. Eplerenone improved left ventricular function in a dose-dependent manner. Central venous pressure and left ventricular end-diastolic pressure were lower, and +/-dP/dt and fractional shortening were higher in group H than group V. Eplerenone also attenuated myocardial fibrosis and reduced left ventricular mRNA expressions of TGF-beta(1) and collagen-III. Our results indicate that treatment with eplerenone improved left ventricular dysfunction and attenuated left ventricular remodeling in rats with heart failure.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Collagen Type III,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Aldosterone,
http://linkedlifedata.com/resource/pubmed/chemical/Spironolactone,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta,
http://linkedlifedata.com/resource/pubmed/chemical/eplerenone
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0031-7012
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright (c) 2005 S. Karger AG, Basel.
|
| pubmed:issnType |
Print
|
| pubmed:volume |
73
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
81-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15467302-Animals,
pubmed-meshheading:15467302-Autoimmune Diseases,
pubmed-meshheading:15467302-Cardiomyopathy, Dilated,
pubmed-meshheading:15467302-Collagen Type III,
pubmed-meshheading:15467302-Dose-Response Relationship, Drug,
pubmed-meshheading:15467302-Electrocardiography,
pubmed-meshheading:15467302-Fibrosis,
pubmed-meshheading:15467302-Hemodynamics,
pubmed-meshheading:15467302-Male,
pubmed-meshheading:15467302-Myocarditis,
pubmed-meshheading:15467302-Myocardium,
pubmed-meshheading:15467302-RNA, Messenger,
pubmed-meshheading:15467302-Rats,
pubmed-meshheading:15467302-Rats, Inbred Lew,
pubmed-meshheading:15467302-Receptors, Aldosterone,
pubmed-meshheading:15467302-Spironolactone,
pubmed-meshheading:15467302-Transforming Growth Factor beta,
pubmed-meshheading:15467302-Ventricular Dysfunction, Left,
pubmed-meshheading:15467302-Ventricular Remodeling
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.
|
| pubmed:affiliation |
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata-shi, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|